vs
Side-by-side financial comparison of Danaos Corp (DAC) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Danaos Corp is the larger business by last-quarter revenue ($262.2M vs $177.4M, roughly 1.5× Pacira BioSciences, Inc.). Danaos Corp runs the higher net margin — 49.9% vs 1.6%, a 48.3% gap on every dollar of revenue. On growth, Danaos Corp posted the faster year-over-year revenue change (6.4% vs 5.0%).
Danaos Corporation is a leading global containership ownership and management firm. It operates a large fleet of modern container vessels, providing long-term charter services to top international container liner operators across major global trade routes, supporting the efficiency and reliability of global supply chains.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
DAC vs PCRX — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $262.2M | $177.4M |
| Net Profit | $130.9M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 47.9% | 3.9% |
| Net Margin | 49.9% | 1.6% |
| Revenue YoY | 6.4% | 5.0% |
| Net Profit YoY | -7.3% | — |
| EPS (diluted) | $7.12 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | — | $196.9M | ||
| Q3 25 | — | $179.5M | ||
| Q2 25 | $262.2M | $181.1M | ||
| Q1 25 | — | $168.9M | ||
| Q4 24 | — | $187.3M | ||
| Q3 24 | — | $168.6M | ||
| Q2 24 | $246.3M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $5.4M | ||
| Q2 25 | $130.9M | $-4.8M | ||
| Q1 25 | — | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-143.5M | ||
| Q2 24 | $141.2M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | — | 1.2% | ||
| Q3 25 | — | 3.5% | ||
| Q2 25 | 47.9% | 4.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | — | -82.8% | ||
| Q2 24 | 56.8% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 3.0% | ||
| Q2 25 | 49.9% | -2.7% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -85.1% | ||
| Q2 24 | 57.3% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | — | $0.05 | ||
| Q3 25 | — | $0.12 | ||
| Q2 25 | $7.12 | $-0.11 | ||
| Q1 25 | — | $0.10 | ||
| Q4 24 | — | $0.38 | ||
| Q3 24 | — | $-3.11 | ||
| Q2 24 | $7.23 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $654.1M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.6B | $653.9M |
| Total Assets | $4.5B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | $654.1M | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | $471.7M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | — | $693.1M | ||
| Q3 25 | — | $727.2M | ||
| Q2 25 | $3.6B | $757.8M | ||
| Q1 25 | — | $798.5M | ||
| Q4 24 | — | $778.3M | ||
| Q3 24 | — | $749.6M | ||
| Q2 24 | $3.3B | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $4.5B | $1.5B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | $4.0B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DAC
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
